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A series of tyrosine-containing peptides 1-12: 
Asp-Ala-Asp-Glu-Tyrg9’( P03H~)-Leu-Ile-Pro-GIn-Gln-Gly-OH (1) 
Asp- Ala- A ~ p - G l u - T y r ~ ~ ’  -Leu-Ile-Pro-Gln-Gln-Gly-OH (2) 
Phe-Leu-Pro-Val-Pro-Glu-Tyr1o6s(PO3Hr)-Ile-Asn-Gln-Ser-Va1-OH (3) 
Phe-Leu-Pro-Val-Pro-Glu-Tyr I o h 8  -1le-Asn-Gln-Ser-Val-OH (4) 
Asp-Asn-Pro-Asp-Tyrl 1JR(P03H2)-Gln-Gln-Asp-Phe-Phe-OH (5 )  
Asp-Asn-Pro-Asp-Tyr I I J 8  -Gln-Gin-Asp-Phe-Phe-OH (6) 
Ala-Glu-Tyrl 73(P03H~)-Leu-Arg-Val-Ala-Pro-Gln-Ser-OH (7) 
Ala-Glu-Tyr 173 -Leu-Arg-Val- Ala-Pro-Gln- Ser-OH (8) 
Ala-Glu-Tyr I 73(P03Hr)-Leu-Arg-VaI-Ala-OH (9 )  
Ala-Glu-Tyr I I 7 3  -Leu- Arg-Val- Ala-OH (10) 
Tyrl I 73(Po3 112)-Leu-Arg-Val-Ala-Pro-Gln-Ser-OH (11) 
Tyr1173 -Leu-Arg-Val-Ala-Pro-Gln-Ser-OH (12) 
(six pairs with and without the tyrosine phosphorylated) has been synthesized. The peptides were derived from 
tyrosine autophosphorylation sites in the epidermal growth factor receptor (EGFR): Tyr 992, 1068, 1148 and 
1173. Peptide 1, derived from the Tyr 992 site, inhibited binding of a 35S-labelled fusion protein containing 
both of the SH2 domains from PLCyl to the phosphorylated EGFR with an ICSO of 8 p ~ .  All of the 
phosphorylated peptides except 11 (1,3,5,7 and 9) inhibited this binding to some degree (20-55%) at 10 p ~ .  
The nonphosphorylated peptides were inactive in this assay. The nonphosphorylated peptides 2, 4, 6, 8, 10 
and 12 were obtained by standard solid-phase synthetic methodologies using both Boc/benzyl and Fmoc/ 
tert-butyl strategies. The phosphorylated peptides 1, 3, 5, 7, 9 and 11 were similarly obtained using a Fmoc/ 
tert-butyl strategy incorporating unprotected N’-Fmoc-Tyr, followed by phosphitylation and oxidation of the 
tyrosine in the resin-bound peptide. In addition, Asp-Ala-Asp-Glu-Phe”r(4-CH~PO~H~)-Leu-Ile-Pro-Gln- 
Gln-Gly-OH (15), an analog of 1 incorporating an enzymatically stable phosphotyrosine mimic, 
4-phosphonomethyl-~-phenylalanine, was synthesized and found to be inactive. 0 Munksgaard 1993. 
Key words; epidermal growth factor receptor: inhibition: phospholipase C;. 1 : phosphorylated peptides; tyrosine phospho- 
rplation; src homology 7 
Abbreviations: Abbreviations of the amino acids are in accord with thc rccommcndations of the IUPAC-IUB as set forth in .I. Bid. Chem. 
264, 668-673 (1989). Additional abbrcviations are defined as they appear in the text and are compiled here: EGF,  epidermal growth fac- 
tor; EGFR, epidermal growth factor receptor; PLC;.l, phospholipase C;.l; C, carboxylic acid; SH2, src homology 2; Pmp, 4-phosphonomethyl- 
L-phenylalanine; ABI, Applied Biosystems, Inc.; HMP. 4-hydroxymethylphenox).methyl; Fmoc, 9-fluorenylmethoxycarbonyl; t-Bu, tert-butyl; 
HOBT, I-hydroxybenzotriazole; DCC, dicyc1ohex)lcarbodiiniide; NMP, N-methylpyrrolidinone; Boc, tert-butyloxycarbonyl; TFA, trifluo- 
roacetic acid; PAM, phenylacetamidomethyl; Bzl, benzyl; HF,  hydrogen fluoride; THF, tetrahydrofuran; DCM, dichloromcthanc; HPLC, 
C-18 reversed-phase high-performance liquid chromatography; CZE, capillary zone electrophoresis; NMR, nuclear magnctic resonance; MS, 
mass spcctra; DMF, i~,~r-dimethylformamide; TFMSA, trifluoromethancsulfonic acid, DMS, dimethyl sulfide; DMAP, 4-dimethylamino- 
pyridine; MeOH. methanol; DIEA, diisopropylethylamine; DMSO, dimethyl sulfoxide; EDT, lJ-dithioethane; AcOH, acetic acid; FAB- 
MS, fast atom bombardment mass spectra; El-MS, clectrospray ionization mass spectra; BrZ. 2-bromobenzyloxycarbonyl; Pmc, f l -  
2,2,5,7.8-pentaniethyIchroman-6-sulfonyl: d. doublet. 
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potent inhibitor of this binding. We also report the 
synthesis and inactivity of 15 (and its dimethyl ester 
precursor 13), an analog of 1 incorporating an enzy- 
matically stable phosphotyrosine mimic, 4-phosphono- 
methyl-L-phenylalanine (Pmp). 
The binding of the epidermal growth factor (EGF) to 
its receptor (EGFR) initiates a complex series of intra- 
cellular events which ultimately culminates in mitoge- 
nesis (1). An essential element in the transduction of 
this mitogenic signal is the ability of the EGFR to phos- 
phorylate specifically tyrosine residues in substrate pro- 
teins (2, 3). Phospholipase Cyl  (PLCyl) is an estab- 
lished, biologically relevant substrate for the EGFR (4). 
Its phosphorylation by the EGFR is dependent upon 
the initial phosphorylation of five tyrosines (Tyr 992, 
1068, 1086, 1148 and 1173) in the noncatalytic carbox- 
ylic acid (C) terminus of the receptor (5). Prior to its 
phosphorylation, PLC y 1 binds to the phosphotyrosine- 
containing C-terminus of the EGFR, thereby facilitat- 
ing its phosphorylation (6). The region of PLCyl in- 
volved in this binding contains two src homology 2 
(SH2) domains, which are highly conserved, noncata- 
lytic sequences of approximately 100 amino acids known 
to bind specifically to sequences containing phospho- 
tyrosine (7, 8). 
In an attempt to disrupt the signal transduction path- 
way involving the phosphorylation of PLCyl by the 
EGFR, we postulated that it should be possible to in- 
hibit specifically their SH2-mediated association with 
small tyrosine-phosphorylated peptides derived from 
the autophosphorylated tyrosines in the EGFR. A sim- 
ilar strategy has previously been applied to the platelet- 
derived growth factor receptor-phosphatidylinositol 
3-kinase mediated signal transduction pathway (9). 
Here we report the synthesis and evaluation of a series 
of peptides 1-12 (Table 1) as inhibitors of PLCy 1 SH2 
domain binding to the phosphorylated EGFR as de- 
termined in a new quantitative assay recently reported 
by us (10). The peptides include both phosphorylated 
(1, 3, 5, 7, 9, 11) and nonphosphorylated (2, 4, 6, 8, 10, 
12) analogs derived from tyrosines autophosphorylated 
in the EGFR (Tyr 992, 1068, 1148 and 1173). We have 
identified peptide 1, derived from Tyr 992, as the first 
CHEMISTRY 
The nonphosphorylated peptides 2, 4, 6, 8, 10 and 12 
in Table 1 were prepared by standard solid-phase syn- 
thetic methodologies (1 1) on an Applied Biosystems 
(ABI) 431A peptide synthesizer. Thus, 2, 4, 10 and 12 
were assembled on 4-hydroxymethylphenoxymethyl 
(HMP) polystyrene resin using a 9-fluorenylmeth- 
oxycarbonyl/tert-butyl (Fmoc/t-Bu) strategy with a 
1 -hydroxybenzotriazole/dicyclohexylcarbodiimide 
(HOBT/DCC) mediated coupling scheme in N-methyl- 
pyrrolidinone (NMP) with the two following deviations 
from the standard. First, the tyrosine was incorporated 
with its phenolic moiety unprotected, so as to render it 
available for subsequent phosphorylation on the resin. 
Second, the terminal amino acid was incorporated as 
its N"-tert-butyloxycarbonyl (Boc) derivative such that 
cleavage of this group could be effected concomitantly 
with cleavage of the peptide from the resin rather than 
in a separate step. This allowed each peptide and its 
phosphorylated counterpart to be obtained from the 
same machine synthesis. These peptides were cleaved 
from the resin, and the protecting groups removed, by 
treatment with trifluoroacetic acid (TFA) and various 
scavengers (12). Peptides 6 and 8 were assembled on 
phenylacetamidomethyl (PAM) polystyrene resin using 
a Boc/benzyl (Bzl) strategy with an HOBT/DCC- 
mediated coupling scheme in NMP. These peptides 
were cleaved from the resin, and the protecting groups 
removed, by treatment with hydrogen fluoride (HF)/ 
anisole. 
Phosphorylated peptides 1,3,5,7,9 and 11 in Table 1, 
TABLE 1 
Synthetic peptides derived from EGFR 
















Asp-Ala-Asp-Glu-Tyrg9' -Leu-Ile-Pro-Gln-Gln-Gly -OH 
Phe-Leu-Pro-Val-Pro-Glu-Tyr'068(P03HZ )-Ile-Asn-Gln-Ser-Val-OH 
Phe-Leu-Pro-Val-Pro-Glu-Tyr106x -1le-Asn-Gln- Ser-Val-OH 
Asp-Asn-Pro-Asp-Tyr '48(P03H2)-Gln-Gln-Asp-Phe-Phe-0H 
Asp-Asn-Pro-Asp-Tyr"48 -Gln-Gln- Asp-Phe-Phe-OH 
Ala-Glu-Tyr' '73(P03H2)-Leu-Arg-Val-Ala-Pro-Gln-Ser-OH 
Ala-Glu-Tyr' 173 -Leu-Arg-Val-Ala-Pro-Gln-Ser-OH 
Ala-Glu-Tyr '73(p03HZ )-Leu-Arg-Val-Ala-OH 
Ala-Glu-Tyr' 173 -Leu-Arg-Val- Ala-OH 
Tyr' 173(PO~HZ)-Leu-Arg-Val-Ala-Pro-Gln-Ser-OH 
T Y ~ ' ' ' ~  -Leu-Arg-Val-Ala-Pro-Gln- Ser-OH 
A S ~ - A ~ ~ - A ~ ~ - G ~ U - P ~ ~ ~ ~ ~ [ ~ - C H ~ P O ( O C H ~ ) ~  1-Leu-Ile-Pro-Gln-GIn-Gly-OH 
Asp-Ala-A~p-Glu-Phe~~~(4-CH2PO3H~) -Leu-Ile-Pro-Gln-Gln-Gly-OH 
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the analogous phosphorylated tyrosine derivatives, were 
prepared according to a recently reported on-the-resin 
phosphorylation procedure (1 3). These peptides were 
first assembled in nonphosphorylated form incorporat- 
ing unprotected N“-Fmoc-Tyr on HMP resin using the 
Fmoc/t-Bu strategy described above. Phosphitylation 
of the resin-bound peptide containing the unprotected 
tyrosine hydroxy group with di-t-Bu-N,N-diethylphos- 
phoramidite and tetrazole in anhydrous tetrahydro- 
furan (THF), and subsequent oxidation with aqueous 
t-Bu hydroperoxide in dichloromethane (DCM) ac- 
cording to the prescribed procedure with the minor 
modifications discussed below, followed by cleavage 
and deprotection with TFA and scavengers, furnished 
the phosphorylated peptides as the only major product. 
Little of the corresponding nonphosphorylated peptides 
was obtained (HPLC). 
Peptides 1-12 were all isolated in good yields by 
preparative C- 18 reversed-phase high-performance liq- 
uid chromatography (HPLC). All peptides were > 959, 
pure by analytical HPLC, which was confirmed by 
capillary-zone electrophoresis (CZE) (except 2, which 
was only 83% pure by CZE, and 5, which did not elute 
under the conditions used). The phosphorylated pep- 
tides 1, 3, 5, 7, 9 and 11 were well separated and faster 
eluting than their nonphosphorylated analogs 2, 4,6,8, 
10 and 12 in HPLC, while they were also well separated 
but slower eluting in CZE using an acidic buffer. All 
peptides exhibited amino acid analyses, nuclear mag- 
netic resonance (NMR) spectra, and mass spectra (MS) 
supportive of their structures. In the ‘H-NMR spectra, 
the doublet due to the aromatic protons orrho to the 
tyrosine hydroxy group was shifted downfield 0.29- 
0.43 ppm in its phosphorylated analog, while that of the 
protons metu was also shifted downfield, but only 0.06- 
0.15 ppm. This deshielding indicated that phosphory- 
lation had indeed occurred on the tyrosine hydroxy 
group. 
The originally reported phosphorylation conditions 
(13) of phosphitylation using 10 equiv. of di-t-Bu-N,N- 
diethylphosphoramidite and 30 equiv. of tetrazole in 
THF (not specifically dried), followed by oxidation with 
20 equiv. of 70% aqueous t-Bu hydroperoxide in DCM 
initially did not work well in our hands. When these 
conditions were first applied to the synthesis of 7, thc 
ratio (determined by HPLC analysis of the crude prod- 
uct) of the desired phosphorylated 7 to the undesired 
nonphosphorylated 8 was only 25/75. When the same 
conditions were applied to the synthesis of 5, the ratio 
of the desired phosphorylated 5 to the undesired non- 
phosphorylated 6 was 55/45. When N,N-dimethyl- 
formambde (DMF) (ABI, peptide synthesis grade, dried 
over 4 A molecular sieves) was substituted for THF 
and DCM in the original procedure in the synthesis of 
7, only the nonphosphorylated 8 was observed. When 
these same conditions were applied to the synthesis of 
5, the ratio of phosphorylated 5 to nonphosphorylated 
6 was 7/93. When NMP (ABI, peptide synthesis grade) 
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was substituted for THF in the original procedure in the 
synthesis of 7, the ratio of phosphorylated 7 to non- 
phosphorylated 8 was 2/98. This problem was resolved 
when the equivalents of di-t-Bu-N,N-diethylphosphor- 
amidite and tetrazole were increased to 50 and 150, 
respectively, and anhydrous T H F  was used. When 
these new conditions were applied to the synthesis of 
7, the ratio of phosphorylated 7 to nonphosphorylated 
8 was 97/3. Similarly, these new conditions applied to 
the synthesis of 5 gave a ratio of phosphorylated 5 to 
nonphosphorylated 6 of 87/13. We concluded that the 
phosphitylation reaction was quite water-sensitive. 
The dimethylphosphonate-containing peptide 13 was 
assembled on PAM resin using a Boc/Bzl strategy with 
an HOBT/DCC-mediated coupling scheme in NMP. 
The N*-Boc-4-dirnethylphosphonomethyl-t-pheny1- 
alanine which was incorporated was prepared by a re- 
cently described asymmetric synthesis (14). This pep- 
tide was cleaved from the resin and the protecting 
groups removed by treatment with HF/p-cresol, leaving 
the dimethyl esters of the phosphonic acid intact. In 
addition to the desired 13, a byproduct whose structure 
was determined to be acetyl-Leu-Ile-Pro-Gln-Gln- 
Gly-OH (14) was isolated. This obviously resulted from 
incomplete coupling of the N”-Boc-Pmp derivative to 
the leucine under the standard conditions of single cou- 
pling with four equivalents of the amino acid employed. 
Treatment of 13 with trifluoromethanesulfonic acid 
(TFMSA)/TFA/dimethyl sulfide (DMS)/rn-cresol 
(10:50:30:10, v/v) as described (14) removed the dim- 
ethyl esters to give the desired 15. This reaction also 
yielded a byproduct whose structure was not deter- 
mined, but whose MS indicated that H20 had been 
eliminated from 15. Peptides 13 and 15 were also iso- 
lated by preparative HPLC and were > 95% pure by 
analytical HPLC. These peptides were 90 and 100% 
pure, respectively, by CZE, and exhibited amino acid 
analyses, NMR spectra and MS supportive of their 
structures. 
BIOLOGY 
The assay employed to study the inhibitory properties 
of the synthetic peptides specifically measures the as- 
sociation between the SH2 domains of PLCy 1 with the 
phosphorylated EGFR, and has recently been de- 
scribed (10). Briefly, a bacterial glutathione-S-trans- 
ferase fusion protein, containing both SH2 domains of 
PLCy1, was labelled in vivn with 35S. This protein 
bound to the purified EGFR (complexed with protein 
A-Sepharose beads) from EGF-treated cells, whereas 
no binding was detected in nontreated cells, thus dem- 
onstrating an absolute requirement for phosphorylated 
receptor. This binding was rapid, reaching apparent 
equilibrium within 10 min. Inhibition experiments were 
performed under apparent equilibrium binding condi- 
tions in which the 3SS-labelled SH2 fusion protein was 
incubated with the phosphorylated EGFR-beads com- 
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three peptides encompassing Tyr 1173, peptides 7, 9 
and 11. When the three C-terminal amino acids of 7 
were deleted to give 9, the inhibitory activity increased. 
However, when the two N-terminal amino acids of 7 
were deleted to give 11, inhibitory activity was abol- 
ished. Thus, some amino acids surrounding the phos- 
phorylated tyrosine in these peptides are necessary for 
significant inhibitory activity, while others appear to be 
deleterious. 
Thirdly, although phosphorylated peptides represent- 
ing Tyr 992, 1068, 1148 and 1173 of the EGFR were 
all significantly active in- this assay, there were clear 
differences. Peptide 1, derived from Tyr 992, was the 
most potent with an ICSO of 8 p ~ .  The second most 
potent peptide was that derived from Tyr 1068, peptide 
3, with an Ic50 of 26 p ~ .  It is very interesting to note 
that in recent studies examining the protection of EGFR 
dephosphorylation by PLCy 1 SH2 fusion proteins, Tyr 
992 was in fact demonstrated to be the highest affinity 
binding site on the EGFR for the SH2 domains of 
PLCy1, followed by Tyr 1068 (15). We are presently 
engaged in efforts to optimize the inhibitory activity of 
these peptides in this binding assay. 
plex in the presence of increasing concentrations of the 
peptides 1-12, 13, 15. All of the phosphorylated pep- 
tides except 11 (1, 3, 5, 7, 9) significantly inhibited 
(20-55%) the binding of the SH2 fusion protein to the 
phosphorylated EGFR at 10 p ~ .  These results are re- 
ported in Fig. 1 as the percentage of maximal binding 
of the 35S-labelled SH2 fusion protein to the phospho- 
rylated EGFR-beads complex vs. peptide concentra- 
tion. The nonphosphorylated peptides 2,4 ,6 ,8 ,10  and 
12, as well as the Pmp analogs 13 and 15, did not in- 
hibit this binding even at 1 mM (data not shown). Pep- 
tide 1, a phosphorylated 11 amino acid peptide encom- 
passing Tyr 992, was the most potent inhibitor, with an 
Ic50 O f  8 pM. 
DISCUSSION 
The most important point to be made concerning the 
activity of the peptides 1-12 in inhibiting the binding of 
the SH2 fusion protein to the phosphorylated EGFR is 
the absolute requirement for a phosphorylated tyrosine. 
Phosphorylated peptides 1,3 ,5 ,7  and 9 inhibited bind- 
ing in this assay 20-55% at 1 0 p ~ ,  whereas all un- 
phosphorylated peptides (2, 4, 6, 8, 10, 12) were with- 
out activity even at 1 mM. The stringency of this 
requirement is highlighted by the loss of activity when 
the phosphate moiety in 1 was changed to a phospho- 
nomethyl moiety in 15. These results are consistent 
with the explanation that these phosphorylated pep- 
tides mimic phosphorylated segments of the C-terminus 
of the EGFR and compete with it for the SH2 domains 
Secondly, the importance of the residues adjacent to 
the phosphorylated tyrosine residue in the peptides is 
emphasized by considering the inhibitory activity of the 
of PLCyl. 
I I I 
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FIGURE 1 
Inhibition of the binding of 35S-labelled PLCy SH2 fusion protein to 
phosphorylated EGFR by phosphorylated peptides. Values are ex- 
pressed as percentage of the radioligand bound as a function of 
peptide concentration; 1, 0;  3, 0; 5,.; 7, 0; 9, A;  11, 0. 
EXPERIMENTAL PROCEDURES 
Materials 
All amino acids are of the L configuration. Purchased 
reagents were obtained from the following sources: Nx- 
Fmoc-Tyr, Bachem Bioscience; Nx-Boc-Tyr, Bachem 
California; all other Na-Fmoc and Na-Boc-amino acids, 
ABI or Bachem California; HMP, Nx-Boc-Phe-PAM, 
Na-Boc-Gly-PAM, and N“-Boc-Ser(Bz1)-PAM poly- 
styrene resins, ABI; piperidine, 4-dimethylaminopyrid- 
ine (DMAP), methanol (MeOH), HOBT, DCC, diiso- 
propylethylamine (DIEA), acetic anhydride, TFMSA, 
dimethyl sulfoxide (DMSO), DMF, DCM and NMP, 
ABI; DMF, DCM and NMP, Burdick and Jackson 
(high-purity grade); anhydrous THF, tetrazole, 1,2- 
ethanedithiol (EDT), anisole, DMS, thioanisole, 
m-cresol, p-cresol, phenol, acetic acid (AcOH) and 
70 % aqueous t-Bu hydroperoxide, Aldrich Chemical; 
TFA, ABI and Halocarbon Products; H20 and CH3CN 
(HPLC quality), Pc13 and HNEt2, EM Science; HF, 
Matheson Gas Products. 
Peptide synthesis 
The peptides were prepared by standard solid-phase 
peptide methodology on an ABI 43 1A Peptide Synthe- 
sizer. Fmoc (ABI Standard Fmoc, Version 1.12) and 
Boc (ABI Standard Boc, Version 1.12) strategies were 
employed (16). Both utilized single couplings with four 
equivalents of the protected amino acid HOBT- 
activated ester formed by reaction with DCC. A typi- 
cal cycle for the coupling of an individual amino acid 
by the Fmoc strategy was: (1) deprotection with 20% 
piperidine in NMP, 21 min; (2) washes with NMP, 
243 
D.J. McNamara et al. 
9 min; (3) coupling of the HOBT-activated ester in 
NMP, 71 min; and (4) washes with NMP, 7 min. At 
the completion of the synthesis, the protected peptide 
resin was washed with DCM and dried at reduced 
pressure. A typical cycle for the coupling of an individ- 
ual amino acid by the Boc strategy was: ( I )  deprotec- 
tion with 25% TFA/DCM for 3 min; ( 2 )  deprotection 
with 50% TFA/DCM for 16min; (3)washes with 
DCM, 3 min; (4) washes with 5 7; DIEA/DCM, 4 min; 
( 5 )  washes with NMP, 5 min; (6)coupling of the 
HOBT-activated ester in NMP, 39 min; (7) addition of 
DMSO to make 15% DMS0/85Y0 NMP, 16min; 
(8) addition of 3.8 equiv. of DIEA, 5 min; (9) washes 
with NMP; (10) capping with 10% acetic anhydride, 
5% DIEA in NMP, 9 min; and (1 1) washes with DCM, 
4 min. After the last amino acid had been coupled, the 
N-terminal Boc group was removed, and the protected 
peptide resin was washed with DCM and dried at re- 
duced pressure. The peptides synthesized by Fmoc 
strategy on HMP resins were obtained by treatment 
with TFA containing various scavengers. Time course 
experiments were performed on individual peptides to 
determine the optimal reaction time. 
Peptide purification 
The crude peptide was initially investigated by analyt- 
ical HPLC to optimize the gradient used in its prepar- 
ative purification. Then, approximately 100 mg of crude 
peptide were dissolved in 2.0 mL of 50°, AcOH/H?O, 
filtered through a 0.45 pm syringe filter, injected onto a 
5.0mL loop, and chromatographed on a Vyda? 
218TP1022 HPLC column (10 pm particle size, 300 A 
pore size, 2.2 x 25 cm). A selected gradient of 0.1 *, 
TFA/CH3CN (B) was used to elute the peptide from 
the column, which was originally in loo:, 0.1 O 0  TFA/ 
HzO (A). For example, the gradient employed for 1 
was: 0% B for 10 min, 0-8;; B over 8 min, and 8-28", 
B over 120 min. A flow rate of 15 mL/min was main- 
tained on a Varian 5000 liquid chromatograph and the 
absorbance of the eluant at 2 15 nm was recorded on a 
Hitachi D-2500 integrator. Individual fractions were 
collected and combined based upon analytical HPLC. 
The combined fractions were concentrated under re- 
duced pressure, diluted with HzO, and lyophilized to 
give the product. 
Peptide analysis 
The peptides were assayed for purity by analytical 
HPLC. One mg of the peptide was dissolved in 1 mL 
of H20, filtered through a 0.45 pm syringe filter, and 
chromatographed on a Vydac 218TP54 HPLC column 
( 5  pm particle size, 300 A pore size, 0.46 x 25 cm) using 
an appropriately selected gradient. A flow rate of 
1.5 mL/min was maintained on a Varian 5500 liquid 
chromatograph and the absorbance of the eluant at 
215 nm was recorded on a Hitachi D-2500 integrator. 
The peptides were also assayed for purity by CZE 
using the same solutions prepared above on an ABI 
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270A analytical capillary electrophoresis system. A 
72 cm x 50 pm ID capillary was used with a buffer of 
20 mM Na citrate, pH 2.5, at a given voltage. The ab- 
sorbance of the eluant at either 200 or 210nm was 
recorded on a Hitachi D-2500 integrator. 
Amino acid analyses were performed on an ABI 
420A-H system utilizing automated hydrolysis and pre- 
column derivatization. Automated vapor-phase hydrol- 
ysis was performed at 180 "C  in 6 N HC1 for 75 min. 
HPLC analysis of the derivatized amino acids was per- 
formed on a 2.1 mm column using a gradient system of 
acetate buffered H20 and C H K N  with UV detection 
at 254 nm. 
'H NMR spectra were determined at 250 MHz on 
a Bruker AM250 spectrometer in D 2 0  or D M s 0 - d ~  
with tetramethylsilane as an internal standard. For pep- 
tides 1-12, only the chemical shifts of the two doublets 
(d) due to the aromatic protons in the tyrosine moiety 
are reported. For peptides 13 and 15, the chemical 
shifts of the methylene protons adjacent to the phos- 
phorus are reported in addition to the aromatic pro- 
tons, as well as the methyl protons of 13. 
The fast atom bombardment mass spectra (FAB- 
MS) were obtained on a VG 7070/E-HF mass spec- 
trometer using a direct target probe, xenon target gas, 
and a thioglycerol matrix. Electrospray ionization mass 
spectra (EI-MS) were obtained from a solution of ap- 
proximatelj 100 ng/pL of sample in MeOH/H20 (50/ 
50) with 3'6 AcOH. The solution was analyzed by 
direct infusion into a Vestec Electrospray interface to 
a Finnigan TSQ 70 mass spectrometer at an approxi- 
mate flow rate of 5 pL/min. The observed ( M +  1)+ or 
( M  + 23) + peak is reported with the calculated value for 
( M  + 1) + or ( M  + 23) + . In the cases of FAB-MS, this 
calculated value is the monoisotopic mass, whereas in 
the case of ES-MS, this calculated value is the average 
mass. 
Biological assaji 
The details of the assay have been recently reported 
(10). Briefly, a bacterial glutathione-S-transferase fu- 
sion protein, containing both SH2 domains of PLCyl, 
was labelled in vivo with 35S. Phosphorylated EGFR 
was purified from EGF-treated 3T3 cells transfected 
with the human EGFR by precipitation with anti- 
EGFR antisera. The resulting immune complex was 
bound to protein A-Sepharose beads. Binding of the 
35S-labelled PLCy 1 SH2 fusion protein (25 nM) to the 
purified EGFR-beads complex (approximately 1 pg of 
receptor/assay) was allowed to proceed to equilibrium 
(20 min) in a total volume of 0.4 mL in the presence of 
the indicated concentrations of peptides. Bound 35S 
fusion protein was separated from free by centrifuga- 
tiop, and radioactivity was determined by scintillation 
counting. Results are expressed in Fig. 1 as the means 
of triplicate determinations standard deviations, and 
were repeated in five separate experiments. 
Inhibition of binding of phospholipase Cy 1 
Phe- Leu- Pro- Val-Pro- Glu- Tyv(PO3 H2)- Ile-Asn - Gln - Ser- 
Val-OH(3). The peptide resin was prepared by a Fmoc/ 
t-Bu strategy by first loading the HMP resin (294 mg, 
0.85 mmol/g, 0.25 mmol) with N"-Fmoc-Val symmetri- 
cal anhydride (0.5 mmol) using DMAP as catalyst. The 
peptide was elongated by the sequential coupling of the 
following amino acids (1 mmol) as their HOBT- 
activated esters (in order of addition): N"-Fmoc-Ser(t- 
Bu), Na-Fmoc-Gln, N"-Fmoc-Asn, N"-Fmoc-Ile, N"- 
Fmoc-Tyr, Na-Fmoc-Glu(0-t-Bu), N"-Fmoc-Pro, Nx- 
Fmoc-Val, N"-Fmoc-Pro, N"-Fmoc-Leu, N"-Boc-Phe. 
One half (363 mg) of the lot (727 mg) was phosphory- 
lated as in 1 (379 mg). The peptide was cleaved as in 
1, but for 7 h (193 mg). Preparative HPLC of the crude 
peptide (97 mg) gave the product as a white solid 
(52 mg). HPLC: 10-50% B/45 min, 17.9 rnin (98.5%); 
CZE: + 30 kV, 200 nm, 26.0 rnin (100 %); amino acid 
analysis: Asx (1) 1.14, Glx (2) 2.15, Ser (1) 0.97, Pro 
(2) 1.94, Tyr (1) 0.89, Val (2) 1.98, Ile (1) 0.95, Leu (1) 
1.00, Phe (1) 0.98; 'H-NMR (D20): 6 7.11 (d, 
( M +  H)+ = 1485.1 (calcd., 1486.6). 
J=8 .3Hz ,  2), 7.19 (d, J=8 .5Hz ,  2); ES-MS: 
Asp - Ala -Asp - Glu - Tyr(POjH2) - Leu - Ile -Pro - Gln - Gln - 
Gly-OH (1). The title compound was prepared by a 
Fmoc/t-Bu strategy by first loading the HMP resin 
(238 mg, 1.05 mmol/g, 0.25 mmol) with Na-Fmoc-Gly 
symmetrical anhydride (0.5 mmol) using DMAP as 
catalyst. The peptide was elongated by the sequential 
coupling of the following amino acids (1 mmol) as their 
HOBT-activated esters (in order of addition): N"- 
Fmoc-Gln, Na-Fmoc-Gln, Na-Fmoc-Pro, NE-Fmoc-Ile, 
N"-Fmoc-Leu, N"-Fmoc-Tyr, Na-Fmoc-Glu(0-t-Bu), 
N"-Fmoc-Asp(0-t-Bu), NE-Fmoc-Ala, N"-Boc-Asp(O- 
t-Bu). The tyrosine was phosphorylated by adding one- 
half (350 mg, 0.12 mmol) of the lot (701 mg) to a rock- 
ing reaction vessel and washing sequentially with DMF 
(3 x 15 mL), DCM (3 x 15 mL), and anhydrous THF 
(3 x 15 mL). To the resin was added anhydrous THF 
(12 mL), followed by di-t-Bu-N,N-diethylphosphor- 
amidite (17) (1.56 g, 6.25 mmol, 50 equiv.) and then 
tetrazole (1.32 g, 18.8 mmol, 150 equiv.). The suspen- 
sion was rocked for 60 min, then drained and washed 
sequentially with anhydrous THF (3 x 15 mL), reagent 
grade (not dried) THF (10 x 15 mL), and DCM 
(7 x 15 mL). The resin was suspended in 12 mL of 
DCM and treated with t-Bu hydroperoxide (70 % aque- 
ous solution, 0.34 mL, 2.5 mmol, 20 equiv.) and rocked 
for 60 min. The suspension was drained, and the resin 
was washed sequentially with DCM ( 5  x 15 mL), DMF 
(5 x 15 mL) and DCM (5  x 15 mL), and dried under 
reduced pressure (359 mg). 
The peptide was cleaved from the polystyrene resin 
and the side chains deblocked by stirring the peptide 
resin with a solution ofTFA (9.5 mL) and H20 (0.5 mL) 
for 2 h at room temperature. The spent resin was col- 
lected by filtration and discarded, and the filtrate was 
concentrated under reduced pressure, diluted with H20, 
and lyophilized (195 mg). Preparative HPLC of the 
crude peptide (150 mg) gave the product as a white 
solid (81 mg). HPLC: 0-15% B/45 min, 28.1 min 
(96.1 %); CZE: + 30 kV, 200 nm, 44.4 rnin (96.5%); 
amino acid analysis: Asx (2) 2.14, Glx (3) 3.13, Gly (1) 
1.22,Ala(l)1.07,Pro(l)0.99,Tyr(l)0.97,Ile(l)0.95, 
Leu (1) 1.00; 'H-NMR (D20): 6 7.11 (d , J=  8.3 Hz, 2), 
(calcd., 1329.3). 
7.21 (d, J =  8.5 Hz, 2); ES-MS: ( M +  H)+ = 1328.8 
Asp-A fa-Asp- Glu- Tyr- Leu-Ile-Pro-Gln- Gln- Gly- OH (2). 
The title compound was prepared from the same inter- 
mediate resin as was 1. The peptide was cleaved by 
treatment of the nonphosphorylated peptide resin 
(227 mg) as in 1 (122 mg). Preparative HPLC of the 
crude peptide (105 mg) gave the product as a white 
solid (60 mg). HPLC: 0-15% B/45 min, 33.6 min 
(96.07:); CZE: + 20 kV, 200 nm, 32.4 min (83.3%); 
amino acid analysis: Asx (2) 2.22, Glx (3) 2.26, Gly (1) 
1.47,Ala(l) 1.28,Pro(l)1.03,Tyr(1)0.56,Ile(l) 1.04, 
Leu (l), 1.00; 'H-NMR (D20): 6 6.81 (d, J =  8.3 Hz, 
(calcd., 1249.3). 
2), 7.12 (d, J =  8.3 Hz, 2); ES-MS ( M +  H)+ = 1248.2 
Phe- Leu- Pro- Val- Pro-Glu- Tyr-Ile-Am-Gln-Ser- Val-OH 
(4). The title compound was prepared from the same 
intermediate resin as was 3. The peptide was cleaved 
by treatment of the nonphosphorylated peptide resin 
(155 mg) as in 3 (71 mg). Preparative HPLC gave the 
product as a white solid (45mg). HPLC: 10-50;/0 
B/45 min, 21.4 rnin (97.6%); CZE: + 30 kV, 200 nm, 
12.4min (99.5%); amino acid analysis: Asx (1) 1.00, 
Glx (2) 1.79, Ser (1) 0.87, Pro (2) 1.54, Tyr (1) 0.74, Val 
(2) 1.62, Ile (1) 0.99, Leu (1) 1.05, Phe (1) 0.84; 'H- 
J =  8.5 Hz, 2); ES-MS: ( M +  H)+ = 1405.9 (calcd., 
1406.6). 
NMR (DzO): 6 6.81 (d, J =  8.4Hz, 2), 7.10 (d, 
Asp- Asn - Pro -Asp- Tyr(POlrH2)- Gln - Gln -Asp- Phe - Phe- 
OH(5). The peptide resin was prepared by a Fmoc/t-Bu 
strategy by first loading the HMP resin (238 mg, 
1.05 mmol/g, 0.25 mmol) with N"-Fmoc-Phe symmet- 
rical anhydride (0.5 mmol) using DMAP as catalyst. 
The peptide was elongated by the sequential coupling 
of the following amino acids (1 mmol) as their HOBT- 
activated esters (in order of addition): N"-Fmoc-Phe, 
N"-Fmoc-Asp(0t-Bu), NE-Fmoc-Gln, N"-Fmoc-Gln, 
Na-Fmoc-Tyr, N"-Fmoc-Asp(0t-Bu), Na-Fmoc-Pro, 
Na-Fmoc-Asn, Na-Boc-Asp(0-t-Bu). One-half (330 
mg) of the lot (660 mg) was phosphorylated as in 1 
(354 mg). The peptide was cleaved as in 1 but for 18 h 
(155mg). Preparative HPLC gave the product as a 
white solid (45 mg). HPLC: 10-502 B/22 min, 
11.3 rnin (99.2%); CZE: +20 kV, 210 nm, no peak 
(30 rnin); amino acid analysis: Asx (4) 3.73, Glx (2) 
2.40, Pro (1) 1.00, Tyr (1) 0.90, Phe (2) 1.83; 'H-NMR 
2); FAB-MS: ( M +  H)+ = 1369.3 (calcd., 1368.5). 
(DMSO): 6 7.05 (d, J =  8.7 Hz, 2), 7.13 (d, J =  9.7 Hz, 
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Asp-Asn-Pro-Asp- Tyr- Gln- Gln-Asp- Phe-Phe- OH (6). The 
title compound was prepared by a Boc/Bzl strategy 
using Boc-Phe-PAM resin (860 mg, 0.58 mmol/g, 
0.5 mmol). The peptide was elongated by the sequen- 
tial coupling of the following amino acids (2 mmol) as 
their HOBT-activated esters (in order of addition): N*- 
Boc-Phe, N"-Boc-Asp(0-Bzl), N*-Boc-Gln, N*-Boc- 
Gln, N~-Boc-Tyr(2-bromo-benzyloxycarbonyl) (BrZ), 
N"-Boc-Asp(0-Bzl), N*-Boc-Pro, N*-Boc-Asn, N*-Boc- 
Asp(0-Bzl). Five hundred milligrams of the total lot 
(1.64 g) were treated as in 8 to give crude material 
(134 mg). Preparative HPLC gave the product as a 
white solid (71 mg). HPLC: 10-50?0 B/22 min, 
13.0 rnin (99.0%); CZE: + 20 kV, 210 nm, 26.7 rnin 
(98.3%); amino acid analysis: Asx (4) 4.14, Glx (2) 
2.06, Pro (1) 0.94, Tyr (1) 0.92, Phe (2) 2.00; 'H-NMR 
(DMSO): 6 6.62 (d, J =  8.4 Hz, 2), 6.98 (d, J =  8.3 Hz, 
2); FAB-MS: ( M + H ) +  = 1288.9 (calcd., 1288.5). 
Ala-Glu-Tyr(P03H2)-Leu-Arg- Val-Alu-Pro-Gln-Ser-OH 
17). The protected peptide resin was prepared by a 
Fmoc/t-Bu strategy by first loading the HMP resin 
(238 mg, 1.05 mmol/g, 0.25 mmol) with N*-Fmoc-Ser(t- 
Bu) symmetrical anhydride (0.5 mmol) using DMAP as 
catalyst. The peptide was elongated by the sequential 
coupling of the following amino acids (1 mmol) as their 
HOBT-activated esters (in order of addition): N*- 
Fmoc-Gln. N"-Fmoc-Pro. N*-Fmoc-Ala. N"-Fmoc-Val. 
(203 mg). Preparative HPLC of the crude peptide 
(186 mg) gave the product as a white solid (130 mg). 
HPLC: 10-50% B/22 min, 9.7 min (98.9%); CZE: 
+ 20 kV, 210 nm, 13.4 min (98.5%); amino acid anal- 
ysis: Glx (2) 1.97, Ser (l), 1.03, Arg (1) 0.98, Ala (2) 
2.02, Pro (1) 0.90, Tyr (1) 0.90, Val (1) 0.99, Leu (1) 
J =  8.5 Hz, 2); FAB-MS: ( M +  H ) +  = 1133.5 (calcd., 
1133.6). 
1.00; 'H-NMR (D20): 6 6.70 ( d , J =  8.5 Hz, 2); 7.01 (d, 
Ala-Glu- Tyr(PO.ZH2)-Leu-Arg- Val-Ah-OH (9). The pep- 
tide resin was prepared by a Fmoc/t-Bu strategy by first 
loading the HMP resin (294 mg, 0.85 mmol/g, 
0.25 mmol) with N*-Fmoc-Ala symmetrical anhydride 
(0.5 mmol) using DMAP as catalyst. The peptide was 
elongated by the sequential coupling of the following 
amino acids (1 mmol) as their HOBT-activated esters 
(in order of addition): N"-Fmoc-Val, N"-Fmoc- 
Arg(Pmc), N"-Fmoc-Leu, N"-Fmoc-Tyr, N"-Fmoc- 
Glu(0-t-Bu), and N"-Boc-Ala. One half (318 mg) ofthe 
lot (635 mg) was phosphorylated as in 1 (329 mg). This 
was stirred with a solution of TFA (10 mL), EDT 
(0.25 mL), thioanisole (0.5 mL), phenol (0.75 g) and 
H2O (0.5 mL) for 3.5 h. The spent resin was collected 
by filtration and discarded. The filtrate was concen- 
trated under reduced pressure to give a syrup which 
was diluted with ether. affordinn a solid. This was col- 
lected, dissolved in HzO, an$ lyophilized (119 mg). 
N"-Fmoc-Arg (~-2,2,5,7,8-pentamethylchroman-6-sulfoPreparative HPLC gave the product as a white solid 
nyl)(Pmc), N"-Fmoc-Leu, N*-Fmoc-Tyr, N"-Fmoc- 
Glu(0-t-Bu), N"-Boc-Ala. One half (312 mg) of the lot 
(624 mg) was phosphorylated as in 1 (312 mg). The 
peptide was cleaved as in 9, but for 4.5 h (141 mg). 
Preparative HPLC gave the product as a white solid 
(95 mg). HPLC: l0-50% B/22 min, 8.7 rnin (99.00,,); 
CZE: + 20 kV, 210 nm, 21.6 rnin (99.2":); amino acid 
analysis: Glx (2) 2.30, Ser (1) 1.06, Arg (1) 1.00, Ala (2) 
2.28, Pro (1) 1.08, Tyr (1) 1.07, Val (1) 1.16, Leu ( I )  
J =  8.6 Hz, 2); FAB-MS: ( M +  H)' = 1213.9 (calcd., 
12 13.5). 
1.19; 'H-NMR (D20): 6 6.99 ( d , J =  8.7 Hz, 2), 7.07 (d, 
Ala-Glu-Tyr-Leu-Arg- Val-Ala-Pro-Gin-Ser-OH (8). The 
title compound was prepared by a Boc/Bzl strategy 
using Boc-Ser(Bz1)-PAM resin (690 mg, 0.72 mmol/g, 
0.5 mmol). The peptide was elongated by the sequen- 
tial coupling of the following amino acids (2 mmol) as 
their HOBT-activated esters (in order of addition): N*- 
Boc-Gln, N"-Boc-Pro, N"-Boc-Ala, N*-Boc-Val, N"- 
Boc-Arg (fl-tosyl), N"-Boc-Leu, N"-Boc-Tyr(BrZ), 
N"-Boc-Glu(0-Bzl), N"-Boc-Ala. Five hundred milli- 
grams of the total lot (1.484 g) were treated with anhy- 
drous H F  (10 mL) and anisole (1 mL) (1 h, 0 ' C). The 
H F  was removed by a stream of N2. The peptide and 
resin were triturated with ether and collected by filtra- 
tion. The peptide was extracted with 50% AcOH/H20 
(4 x 25 mL), and the extracts were concentrated under 
reduced pressure, diluted with H20, and lyophilized 
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(68mg). HPLC: O-i5% B/45 min, 15.3 rnin (95.8%), 
22.0 rnin (10, 4.2%); CZE: + 20 kV, 200 nm, 20.3 rnin 
(97.6y0); amino acid analysis: Glx (1) 1.17, Arg (1) 
0.92, Ala (2) 2.17, Tyr (1) 0.93, Val (1) 0.99, Leu (1) 
J =  8.6 Hz, 2); ES-MS: ( M +  H ) +  = 901.3 (calcd., 
90 1.9). 
1.00; 'H-NMR (D20): 6 7.09 (d,J= 8.6 Hz, 2) 7.18 (d, 
Ala-Glu- Tvr-Leu-Arg-Val-Ala-OH (10). The title com- 
pound was prepared from the same intermediate resin 
as was 9. The peptide was cleaved by treatment of the 
nonphosphorylated peptide resin (245 mg) as in 9, but 
for 2 h (102 mg). Preparative HPLC gave the product 
as a white solid (74 mg). HPLC: 0-15% B/45 min, 
21.3 rnin (100%); CZE: + 20 kV, 200 nm, 11.8 rnin 
(99.57;); amino acid analysis: Glx (1) 1.11, Arg (1) 
0.92, Ala (2) 1.81, Tyr (1) 0.90, Val (1) 0.92, Leu (1) 
J =  8.3 Hz, 2); ES-MS: ( M +  H ) +  = 821.0 (calcd., 
821.9). 
1.00; 'H-NMR(D20): 66.80(d,J=8.3 Hz,2)7.11 (d, 
Ti.ifPOjH2)-Leu-Arg- Val-Ala-Pro-Gln-Ser-OH(ll). The 
peptide resin was prepared by a Fmoc/t-Bu strategy by 
first loading the HMP resin (294 mg, 0.85 mmol/g, 
0.25 mmol) with N"-Fmoc-Ser(t-Bu) symmetrical an- 
hydride (0.5 mmol) using DMAP as catalyst. The pro- 
tected peptide was elongated by the sequential coupling 
of the following amino acids (1 mmol) as their HOBT- 
activated esters (in order of addition): N"-Fmoc-Gln, 
Inhibition of binding of phospholipase Cy 1 
treatment of 13 (20mg) with a solution of TFMSA/ 
TFA/DMS/m-cresol(O.2 mL/1 mL/0.6 mL/0.2 mL) at 
0 "C for 2 h. The solution was diluted with ether to 
afford a solid, which was collected by filtration, dis- 
solved in Hz0, and lyophilized to give a hygroscopic 
solid. Preparative HPLC of the crude peptide gave the 
product as a white solid (12 mg). HPLC: 10-257" 
B/45 min, 29.0 min (96.6%); CZE: + 25 kV, 210 nm, 
39.1 min (100%); amino acid analysis: Asx (2) 1.70, 
Glx (3) 2.38, Gly (1) 1.05, Ala (1) 1.00, Pro (1) 1.39, 
Ile (1) 1.09, Leu (1) 0.91, Pmp (1) 1.31 [elutes with the 
approximate retention time of His (IS)]; 'H-NMR 
(DzO): 6 3.0 (d, J =  21 Hz, 2, CHlP), 7.2 (multiplet, 
4); FAB-MS: ( M +  H)' = 1326.6 (calcd., 1326.6). 
Also isolated in the preparative HPLC was a by- 
product as a hygroscopic white solid (3 mg). HPLC: 
10-25% B/45 min, 30.9 min (88.9%). FAB-MS: 
(M+H)+  = 1308.6 [calcd. for ( M + H ) +  of 15 minus 
18(H20), 1308.61. 
N"-Fmoc-Pro, N"-Fmoc-Ala, N"-Fmoc-Val, N"-Fmoc- 
Arg(Pmc), N"-Fmoc-Leu, N"-Boc-Tyr. One half 
(294 mg) of the lot (587 mg) was phosphorylated as in 
1 (308 mg). The peptide was cleaved as in 9 (128 mg). 
Preparative HPLC gave the product as a white solid 
(66 mg). HPLC: 10-20% B/45 min, 20.5 min (98.5%); 
CZE: + 20 kV, 200 nm, 24.0 min (99.8%); amino acid 
analysis: Glx (1) 0.99, Ser (1) 0.93, Arg (1) 0.94, Ala ( I )  
1.08, Pro (1) 1.00, Tyr (1) 0.95, Leu (1) 1.10, Val (1) 
J =  8.9 Hz, 2); ES-MS: ( M +  H)+ = 1014.1 (calcd., 
1014.1). 
1.02; 'H-NMR (D20): 6 7.02 (d, J =  8.9 Hz, 2) 7.07 (d, 
Tyr-Leu-Arg-Val-Ala-Pro-Gln-Ser-OH (12). The title 
compound was prepared form the same intermediate 
resin as was 11. The peptide was cleaved by treatment 
of the nonphosphorylated peptide resin (210 mg) as in 
10) (95 mg). Preparative HPLC gave the product as a 
white solid (73 mg). HPLC: 10-20% B/45 min, 
23.0 min (98.8%); CZE: + 20 kV, 200 nm, 13.8 min 
(99.4%); amino acid analysis: Glx (1) 1.04, Ser (1) 
0.99, Arg (1) 1.04, Ala (1) 1.09, Pro (1) 1.00, Tyr (1) 
0.95, Val (1) 1.09, Leu (1) 1.17; 'H-NMR (D20): 6 6.73 
( M +  H)+ = 933.4 (calcd., 934.1). 
(d, J z 8 . 5  Hz, 2) 7.00 (d, J=8.5Hz,  2); ES-MS: 
Asp-A la- Asp- Glu- Phe(4- CH2PO(OCHj)2 J -  Leu- Ile- Pro- 
Gln- Gln- Gly- OH (1 3) and Acetyl-Leu-Ile-Pro- Gln- Gln- 
Gly-OH (14). The title compound 13 was prepared by 
a Boc/Bzl strategy using Boc-Gly-PAM resin (707 mg, 
0.70 mmol/g, 0.5 mmol). The peptide was elongated by 
the sequential coupling of the following amino acids 
(2 mmol) as their HOBT-activated esters (in order of 
addition): N"-Boc-Gln, Nu-Boc-Gln, Nu-Boc-Pro, Na- 
Boc-Ile, N"-Boc-Leu, Na-Boc-Phe[ 4-CHzPO(OCH3)2] 
(14), N"-Boc-Glu(0-Bzl), N"-Boc-Asp(0-cyclohexyl), 
N"-Boc-Ala, N"-Boc-Asp(0-cyclohexyl). Six hundred 
milligrams of the total lot (1.222 g) were treated as in 
8 except p-cresol was substituted for anisole. Prepar- 
ative HPLC of the crude peptide (108 mg of the total 
225 mg) gave 13 as a white solid (58 mg). HPLC: 10- 
40% B/45 min, 23.6 min (96.4%); CZE: + 20 kV, 
210 nm, 33.5 min (90.3%); amino acid analysis: Asx 
(2) 0.96, Glx (3) 2.11, Gly (1) 0.87, Ala (1) 1.00, Pro 
(1) 0.83, Ile (1) 0.96, Leu (1) 1.00; dimethylphospho- 
nomethylphenylalanine (1) not determined; 'H-NMR 
J =  10.9 Hz, 6, OMe), 7.25 (multiplet, 4); FAB-MS: 
( M +  Na)+ = 1376.2 (calcd., 1376.6). 
Also isolated in the preparative HPLC of the crude 
peptide was 14 as a white solid (28 mg). HPLC: 10- 
40% B/45 min, 19.7 min (97.7%); CZE: + 25 kV, 
210 nm, 37.6 min (100%); amino acid analysis: Glx (2) 
2.25, Gly (1) 0.58, Pro (1) 0.75, Ile (1) 1.00, Leu (1) 
0.90; FAB-MS: ( M +  23)+ = 719.3 (calcd., 719.4). 
(D20): 6 3.34 (d, J=21.4 Hz, 2, CHzP), 3.72 (d, 
Asp-Ala-Asp-Glu-Phe (4-CH2PO~H2)-Leu-Ile-Pro-Gln- 
Gln-Gly-OH (15). The title compound was prepared by 
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